Parecoxib
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Parecoxib: From Perioperative Pain Management to Migraine Disorder
One-Sentence Summary
Parecoxib is an injectable COX-2 inhibitor (a prodrug of valdecoxib), marketed in Singapore with 6 valid registrations. The TxGNN model predicts it may be effective for migraine disorder. Support is limited: no registered clinical trials and 1 small pilot clinical comparison study (with supporting preclinical papers) are currently available.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence records compiled for this report (parecoxib is generally known as a short-term injectable analgesic in the perioperative setting) |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.55% |
| Evidence Level | L3 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 6 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Parecoxib is a prodrug of valdecoxib, a selective COX-2 inhibitor. Detailed mechanism-of-action data was not available in the data compiled for this report, but the class mechanism is well known: blocking COX-2 reduces prostaglandin (PGE2) production, which drives inflammation and pain.
Migraine is not a distant concept from this mechanism. Preclinical work shows that COX-2-dependent PGE2 synthesis is linked to CGRP release in rat trigeminal ganglia cells (PMID 21394197), and parecoxib affected plasma protein extravasation and c-fos expression in a rat model of trigeminovascular activation (PMID 16492237). These pathways are involved in migraine pain.
A small pilot clinical study (PMID 21996647) compared intravenous parecoxib with sumatriptan and rizatriptan in acute migraine attacks. However, its design and the strength of its findings cannot be confirmed from the information available, so it should be treated as hypothesis-generating only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21996647 | 2011 | Clinical comparative (pilot) study | Clinical Neuropharmacology | Compared IV parecoxib 40 mg, oral rizatriptan 10 mg and subcutaneous sumatriptan in acute migraine attacks; design details and results not confirmed |
| 21394197 | 2011 | Preclinical (in vitro) | PLoS One | IL-1β stimulates COX-2-dependent PGE2 synthesis and CGRP release in rat trigeminal ganglia cells |
| 16492237 | 2006 | Preclinical (rat) | Headache | Effects of parecoxib on meningeal plasma protein extravasation and c-fos expression in a trigeminovascular model |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14149P | Dynastat Powder and Solvent for Solution for Injection 40mg | Lyophilised powder for injection | Not listed in the records |
| SIN17079P | Paracox Powder for Solution for Injection 40mg/vial | Lyophilised powder for injection | Not listed in the records |
| SIN16913P | Parecoxib WB Powder for Solution for Injection 40mg/vial | Lyophilised powder for injection | Not listed in the records |
| SIN16721P | Parecoxib Sandoz Powder for Solution for Injection 40mg | Lyophilised powder for injection | Not listed in the records |
| SIN17012P | Parecoxib-AFT Powder for Solution for Injection 40mg | Lyophilised powder for injection | Not listed in the records |
One further valid registration (SIN16666P, Parecoxib Mylan 40mg/vial) is also held, bringing the total to 6. All are single-ingredient injectable products.
Safety Considerations
Please refer to the package insert for safety information.
The following concerns come from the literature compiled for this report rather than from label text:
- COX-2 inhibitors as a class carry cardiovascular and thrombotic risks (PMIDs 18516356, 34592918).
- Valdecoxib has been associated with potentially life-threatening skin reactions (PMID 16393277).
- Parecoxib is available only as an injection, which limits its practicality for repeated or outpatient migraine treatment.
Conclusion and Next Steps
Decision: Hold
Rationale: The model score is high and the COX-2/CGRP mechanism is biologically plausible, but the clinical evidence is a single small pilot comparison with unconfirmed design and results, and no registered trials exist. Together with class cardiovascular safety concerns and the injection-only route, this supports a research question rather than a move to development.
To proceed, the following is needed:
- Full-text review of PMID 21996647 to confirm design, sample size, endpoints and results
- Package insert warnings, contraindications and approved indications from HSA (not available in the data compiled for this report)
- Mechanism-of-action data from DrugBank
- Drug interaction data (none found in the compiled data)
- Assessment of route compatibility: whether an injectable is suitable for acute migraine care
- A registered, adequately powered randomised trial in acute migraine, with a cardiovascular risk assessment
Other predicted indications (for reference): Headache disorder and rheumatoid arthritis have only indirect or class-level literature and remain research questions. Migraine with brainstem aura, trigeminal autonomic cephalalgia, kyphoscoliotic heart disease, atrophoderma vermiculata and ulerythema ophryogenesis have no supporting evidence. Pulmonary hypertension is supported only by a piglet sepsis study in which parecoxib did not suppress thromboxane synthesis. These are not recommended for advancement at this time.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.